Phase 4
Completed N=528
CeraVe Diabetes Mellitus
Diabetes Complications
Source: ClinicalTrials.gov NCT04724967 ↗
Enrolled (actual)
528
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcomePrimary: Percentage of Participants Reporting Adverse Events (AE) — 0 percentage of participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to evaluate the safety and efficacy of the CeraVe Diabetic Skin Line for the improvement of skin condition in patients with diabetes mellitus.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Reporting Adverse Events (AE) |
— | — |
| PRIMARY Number of Participants at Each GAIS Grading Scale |
223; 224; 72; 9; 0 | — |
| PRIMARY Number of Participants at Each Dry Skin Scale |
271; 219; 28; 7; 3; 386 | — |
Eligibility Criteria
Inclusion Criteria
- Men or women between the ages of 18 and 75 years of age.
- Willing to provide written informed consent.
- A diagnosis of diabetes mellitus (DM).
- DM-related skin changes classified into one or more of the following four categories: i) skin lesions associated with DM; ii) infections; iii) cutaneous manifestations of DM complications; iv) skin reaction to DM treatment.
Exclusion Criteria
- History of allergy, anaphylaxis or hypersensitivity to any of the ingredients in CeraVe Hydrating Cleanser or Moisturizing Cream
- History of allergic contact dermatitis secondary to cleansers or moisturizers.
- Has a heightened immune response to common allergens, especially inhaled, topical or food allergens (atopy).
- Has any clinical manifestation in the treatment are(s) or other disorders that, in the investigator's opinion, may affect assessments or the study products.
- Inability to attend all study visits and follow treatment regimen.
Data sourced from ClinicalTrials.gov (NCT04724967). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.